

# **Key investor information**

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

### NHS-SICAV II - MCM ISRAELI IT-SECURITY FUND, class E USD (LU1345292533)

a sub-fund of NHS-SICAV II

Management Company: Fuchs Asset Management S.A.

## Objectives and investment policy

#### **Objectives**

The sub-fund's main objective is to achieve a consistent outperformance, relative to its benchmark, the TASE-BlueStar Israel Global Technology Index, by selecting stocks within IT-Security sector based on quantitative models. The strategy will then overweight those stocks within a large and diversified basket of global IT security stocks (actively managed).

#### Investment policy

The sub-fund aims to maximize the increase in value of the portfolio with agile response to the Israel, London and US markets within the IT security sector. In order to achieve its investment objective, the sub-fund will mainly invest in equities that are members of the BGTH Index and will overweight the equities related to the IT security sector within a portfolio of global technology stocks in accordance with the "General Investment Restrictions" of the prospectus.

The sub-fund will invest (up to 100% of its net assets) in equities mainly listed on the US, London and Israel markets.

The sub-fund may use financial derivative instruments for hedging and investment purposes. Investment in non-reference currency financial instruments is allowed provided by the fact that currency exposure is hedged. There is however, no guarantee or assurance that such coverage will be effective.

The sub-fund may also invest up to 100% of its net assets in liquid instruments, such as cash deposits, money market UCITS.

The sub-fund is actively managed. While the sub-fund compares its performance against the TASE-BlueStar Israel Global Technology Index, it does not try to replicate this benchmark and freely selects the securities that it invests in. The deviation with this benchmark can be significant.

The reference currency of the sub-fund is expressed in EUR. The currency of the share class is expressed in USD.


The investor has the right to redeem his shares on demand. The dealing in shares is carried out on each complete bank business day in Luxembourg. The attention of the investor is drawn to the fact that in exceptional circumstances, the possibility for the investor to request the redemption of his shares may be limited or suspended.

These shares are capitalisation shares. Income and capital gains are reinvested.

#### Recommendation

This fund may not be appropriate for investors who plan to withdraw their money within 4 - 5 years.

# Risk and reward profile



#### What does this synthetic indicator mean?

- The shares of class E USD are classified in category 7 because the value
  of the share may be subject to high variations and consequently the risk
  of loss and the opportunity of gain may be high.
- The risk category has been determined on the basis of historical and simulated data and may not be a reliable indication of the future risk profile.
   The risk and reward category shown does not necessarily remain unchanged and the categorisation of the fund may shift over time.
- The lowest category does not mean a risk-free investment.
- Repayment of the initial investment is not guaranteed.

# Which materially relevant risks are not adequately captured by the synthetic indicator?

 Credit risk: the sub-fund can be indirectly invested in securities whose credit rating may decline, it is consequently exposed to credit risk.

- Liquidity risk: the sub-fund will invest in Transferable Securities of smaller companies which may be less liquid.
- Counterparty risk: the sub-fund will invest in OTC derivatives for investment and hedging purposes.
- *Operational risk:* the sub-fund is subject to risks through operational or human error. The management company is monitored by independent internal and external auditors, as well as by the regulators.
- Emerging market risk: Emerging, frontier and other markets may be subject to increased political, regulatory and economic instability, poor transparency, safekeeping issues and greater financial risks.
- Risks from the use of derivatives: the sub-fund will invest on an ancillary basis in financial derivatives. Financial derivative instruments can introduce leverage risks and lead to volatility.
- Risks related to investment in currencies: The sub-fund's investments
  may be acquired directly or indirectly in other national currencies than its
  reference currency. This can have a negative impact on the Fund depending on volatility in currency markets.

#### How can I get more information about the risks of the sub-fund?

Additional information concerning the risks of investment in the sub-fund is indicated in the corresponding section of the prospectus of the fund which is available at the Management Company and on the website <a href="www.fuchs-am.com">www.fuchs-am.com</a>.

## **Charges**

One-off charges taken before or after you invest	
Entry charge	0.00%
Exit charge	0.00%
This is the maximum that might be taken out of your money before it is invested and before the proceeds of your investment are paid out.	
Charges taken from the fund over a year	
Ongoing charge	1.01%
Charges taken from the fund under certain specific conditions	
Performance fee	None

The charges paid by an investor are used to cover the running costs of the fund, including the costs of marketing and distribution of shares. These charges reduce the potential increase in value of an investment in this fund.

The entry and exit charges shown correspond to a maximum percentage which might be deducted from the investor's capital invested into the fund. In some

cases, the investor might pay less. The investor may contact his financial adviser or intermediary to be informed on the actual entry and exit charges.

The conversion of part or all of the shares into shares of another sub-fund or another share class is free of charge.


The ongoing charges relate to the annual charges; they were calculated on 31.12.2021. The ongoing charges may vary from year to year.

The figure of the ongoing charges excludes:

Securities transaction charges, except for the charges related to the purchase and the sale of target funds.

For further information concerning charges, please consult the heading "Expenses charged to the SICAV" of the fund's prospectus, which is available at the registered office of the Management Company and on www.fuchs-am.com.

## Past performance



Past performance is not a reliable indicator of future performance.

All charges and fees, except for the entry and exit charges, were taken into account.

The past performance was calculated in USD.

The sub-fund was created in 2016.

This share class was created in 2018.

The sub-fund does not aim to track the composition of its benchmark index.

### **Practical information**

#### Depositary

UBS Europe SE, Luxembourg Branch

#### Additional information and availability of the prices

Additional information about the fund, copies of its prospectus, its latest annual and semi-annual report and the latest prices of shares of NHS-SICAV II may be obtained free of charge from the registered office of the Management Company or on <a href="www.fuchs-am.com">www.fuchs-am.com</a>.

The prospectus, the latest annual and semi-annual report of the fund are available in English. The Management Company may inform you about other languages in which these documents are available.

The details of the up-to-date remuneration policy of the Management Company, including a description of how remuneration and benefits are calculated, are available on <a href="www.fuchs-am.com">www.fuchs-am.com</a>. A paper copy will be made available free of charge upon request.

#### Liability

Fuchs Asset Management S.A. may be held liable only on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the fund.

#### **Taxation**

The fund is subject to Luxembourg tax legislation. The investor's fiscal residence might have an impact on his personal tax position.

#### Specific information

The sub-fund NHS-SICAV II - MCM ISRAELI IT-SECURITY FUND may also issue other share classes.

Information about other share classes that may be marketed in your country is available at the Management Company.

This key investor information document provides information about a sub-fund of NHS-SICAV II that may consist of several sub-funds. The prospectus and the annual and semi-annual reports are prepared for the entire fund.

The assets and liabilities of a sub-fund are segregated pursuant to the law so that the commitments and liabilities of one sub-fund do not affect the other sub-funds

The investor has the right to convert his investment from shares in one sub-fund into shares of the same sub-fund or of another sub-fund. The investor can obtain information about how to subscribe, redeem and convert in the prospectus of the fund.